A better understanding of the science and reality of obesity is urgently needed.

Efforts to prevent and treat obesity need to be grounded in science. A historical focus on individual responsibility has been ineffective in halting the rise in obesity prevalence. There needs to be a better understanding of environmental and biological drivers of weight gain to help reduce weight bias and stigma and identify more effective policies for action.

Déclaration de conflit d'intérêts

ClR reports grants from Irish Research Council, Science Foundation Ireland, Anabio and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson and Johnson, Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer-Ingelheim. He is also a previous Investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He divested stock holdings in Keyron in September 2021. PS reports payment for lectures from Novo Nordisk. BO is President of the Asia Oceania Association for the Study of Obesity, which has received financial support from Novo Nordisk. His is a member of the working party to establish the Burden of Obesity in Asia Pacific and Chair of the Steering Committee of the ACTION APAC Study, both of which received financial support from Novo Nordisk.